Valence-Logo
Beliebt
Anmelden
Loading data for SCNX — first visit, this takes a few seconds.

Zur Watchlist hinzufügen

Scienture Inc.

NasdaqCM: SCNX · Echtzeitkurs · USD
0.46
-0.01 (-2.13%)
Zum Schluss: Aug 18, 2026, 8:00 PM

Scienture Inc. (SCNX) Stock Price, Analysis & Data

-2.13%

Keine Daten verfügbar

Geldn/a
Marktkapitalisierung18.76 Mio
Umsatz (TTM)821.32K
Nettogewinn (TTM)-37.95 Mio
Betan/a
EPS (ttm)-1.98
KGV (TTM)n/a
Forward-KGVn/a
KBV (TTM)0.28
KUV (TTM)22.84
Earnings Daten/a
Briefn/a
Volumen525,504
Ø Vol. (20D)2,538,061
Eröffnung0.46
Vortagesschluss0.47
Tagesspanne0.44 - 0.48
52-Wk Range0.24 - 2.60
Analystn/a
Kurszieln/a
Dividendenn/a
Ex-Dividenden-Datum19. Juli 2024

Über SCNX

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left vent...

[Mehr lesen]
Branche Pharmaceutical Retailers
Sektor Healthcare
IPO Datum Feb 6, 2014
Mitarbeiter 4
Börse NasdaqCM
Tickersymbol SCNX
Website https://scienture.com
Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von Scienture 431.61K, ein Anstieg von 215.87% im Vergleich zum Vorjahr (136.64K). Der Gewinn lag bei -41.51 Mio, ein Rückgang von -557.9 %.

Finanzberichte

Gewinnüberraschung

Scienture hat die Quartalszahlen am Aug 13, 2026 veröffentlicht:
  • Umsatz von $56.33K verfehlt die Erwartungen um $0, mit 449.08% Wachstum im Jahresvergleich.
  • EPS von -0.07 übertrifft die Erwartungen um 0.02, mit -Infinity% Rückgang im Jahresvergleich.
    news image

    vor 6 Tagen · InvestorsHub

    SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product

    SCIENTURE has commercially launched REZENOPY, its 10 mg naloxone nasal spray, and fulfilled initial purchase orders to U. S.

    news image

    vor 6 Tagen · Benzinga

    EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US

    Pharmaceutical firm Scienture Holdings, Inc. (NASDAQ:SCNX) on Wednesday officially initiated the commercial rollout of Rezenopy, a 10-milligram naloxone hydrochloride nasal spray. The company has succ...

    news image

    vor 2 Monaten · Benzinga

    EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch

    Scienture Holdings Inc. (NASDAQ:SCNX) said Tuesday that its opioid overdose treatment Rezenopy (naloxone HCl) Nasal Spray 10 mg has been added to the formulary of a large national health plan, broaden...

    news image

    vor 5 Monaten · Associated Press Finance

    BC-Most Active Stocks

    Elong Power Holding Ltd. 79,546,080 0.0559

    news image

    vor 8 Monaten · TipRanks

    Scienture, BlinkRx announce strategic collaboration to expand access to Arbli

    Scienture (SCNX) announced a strategic collaboration to expand national access to Arbli, the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium. Arbli is expected to be...

    Seite 1 von 2